Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Apollomics Inc WT (APLMW)

Apollomics Inc WT (APLMW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Apollomics Regains Full Compliance with Nasdaq Listing Requirements GlobeNewswire - Mon Jul 13, 7:00AM CDT

FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple...

APLM : 18.21 (-3.45%)
APLMW : 0.0190 (+1.60%)
Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia GlobeNewswire - Wed Jun 24, 3:15PM CDT

FOSTER CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple...

APLM : 18.21 (-3.45%)
APLMW : 0.0190 (+1.60%)
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress GlobeNewswire - Mon Apr 27, 7:00AM CDT

Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential. To date, more than...

APLM : 18.21 (-3.45%)
APLMW : 0.0190 (+1.60%)
Apollomics Inc. Announces $2.0 Million Bridge Financing GlobeNewswire - Wed Apr 1, 6:00AM CDT

FOSTER CITY, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced that it has entered into a $2.0 million unsecured Convertible...

APLM : 18.21 (-3.45%)
APLMW : 0.0190 (+1.60%)
Apollomics Reports First Half 2025 Financial Results GlobeNewswire - Mon Dec 22, 2025

FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple...

APLM : 18.21 (-3.45%)
APLMW : 0.0190 (+1.60%)
Apollomics Announces Settlement of Cayman Litigation GlobeNewswire - Wed Nov 19, 2025

FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement”...

APLM : 18.21 (-3.45%)
APLMW : 0.0190 (+1.60%)
Apollomics Announces Changes to its Board of Directors and Composition of Committees GlobeNewswire - Mon Nov 17, 2025

FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today...

APLM : 18.21 (-3.45%)
APLMW : 0.0190 (+1.60%)
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation GlobeNewswire - Wed Oct 15, 2025

FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing...

APLM : 18.21 (-3.45%)
APLMW : 0.0190 (+1.60%)
Apollomics, Inc. Company Operational Continuity Update GlobeNewswire - Mon Oct 13, 2025

FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced the following company operational update. Apollomics...

APLM : 18.21 (-3.45%)
APLMW : 0.0190 (+1.60%)
Nasdaq Halts Apollomics Inc., Ltd. GlobeNewswire - Wed Sep 17, 2025

NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market ® (Nasdaq: NDAQ) announced that trading was halted on September 17, 2025 in Apollomics Inc., Ltd. at 14:37:17 Eastern Time for additional...

NDAQ : 92.09 (+1.85%)
APLM : 18.21 (-3.45%)
APLMW : 0.0190 (+1.60%)

Barchart Exclusives

Tesla Missed by 38% But Elon Musk Is Not Worried. Here’s What TSLA Investors Should Make of That. Barchart - Sun Jul 26, 4:38PM CDT
Tesla posted mixed Q2 results, but CEO Elon Musk assured investors of incredible returns following heavy capex. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.